<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Saudi Med</journal-id>
      <journal-id journal-id-type="publisher-id">ASM</journal-id>
      <journal-title-group>
        <journal-title>Annals of Saudi Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0256-4947</issn>
      <issn pub-type="epub">0975-4466</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">20103968</article-id>
      <article-id pub-id-type="pmc">2850192</article-id>
      <article-id pub-id-type="publisher-id">ASM-30-88</article-id>
      <article-id pub-id-type="doi">10.4103/0256-4947.59371</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Images</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Reactive macrophage activation syndrome in a patient with parvovirus B19 infection, lymphocytic lichenoid vasculitis, urticaria and angioedema</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Soldo-Juresa</surname>
            <given-names>Dragica</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Radman</surname>
            <given-names>Maja</given-names>
          </name>
          <xref ref-type="aff" rid="AF0002">b</xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pejsa</surname>
            <given-names>Vlatko</given-names>
          </name>
          <xref ref-type="aff" rid="AF0003">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bozikov</surname>
            <given-names>Velimir</given-names>
          </name>
          <xref ref-type="aff" rid="AF0003">c</xref>
        </contrib>
      </contrib-group>
      <aff id="AF0001"><label>a</label>From the University Hospital Vuk Vrhovac, Zagreb, Croatia</aff>
      <aff id="AF0002"><label>b</label>From the Department of Endocrinology, University Hospital Centre Split, Split, Croatia</aff>
      <aff id="AF0003"><label>c</label>From the Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia</aff>
      <author-notes>
        <corresp id="cor1">Correspondence: Maja Radman &#xB7; Department of Endocrinology University Hospital Centre Split Soltanska 1 Split 21000 Croatia &#xB7; T :00385-21-557400 &#xB7; <email xlink:href="maja.radman1@st.htnet.hr">maja.radman1@st.htnet.hr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2010</year>
      </pub-date>
      <volume>30</volume>
      <issue>1</issue>
      <fpage>88</fpage>
      <lpage>89</lpage>
      <permissions>
        <copyright-statement>&#xA9; Annals of Saudi Medicine</copyright-statement>
        <copyright-year>2010</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>A 47-year-old woman had a history of episodic acute intermittent angioedema and urticaria with moderate pruritus for one month. She was on 10 mg of loratadine daily. She had a fever of 39&#xB0;C, arthralgia, fatigue, and angioedema of the upper respiratory tract. Laboratory results are shown in <xref ref-type="table" rid="T0001">Table 1</xref>. She had elevated IgE (206 kU/L). The immunoassay for C1-esterase inhibitor was normal. She was treated with H1- and H2-blocking antihistamines, and methylprednisolone intravenously (1 mg/kg/day). Culture results and viral titers were negative except for a high positive titer of specific IgG antibody to parvovirus B19 of 11.1 (positive titer &gt;1). On the third week of hospitalization, she deteriorated rapidly and developed a macular rash on the trunk and extremities with generalised lymphadenpathy, liver dysfunction and disseminated intravascular coagulopathy (DIC) (<xref ref-type="fig" rid="F0001">Figure 1</xref>). A skin biopsy specimen was compatible with lymphocytic lichenoid vasculitis. An inflammatory pattern centered on the basal layer of the epidermis and upper dermis in a dense band-like distribution. Direct immunofluorescence showed no IgG, IgA, IgM, C3, C1q and fibrinogen deposits. A bone marrow aspirate showed hemophagocytosis (<xref ref-type="fig" rid="F0002">Figure 2</xref>). Parvovirus B19 DNA was detected by the polymerase chain reaction (PCR) in bone marrow (<xref ref-type="fig" rid="F0003">Figure 3</xref>). Macrophage activation syndrome was confirmed. The patient was treated with methylprednisolone 250 mg/day intravenously and intravenous immunoglobulin (IVIG) 0.55 g/kg BW/day for five consecutive days, followed by methylprednisolone 1 mg/kg daily. Fresh frozen plasma and enoxaparin were administered. Two days after treatment, she improved. Monthly infusions of IVIG were continued for 6 months. Corticosteroids were tapered gradually to 8 mg of methylprednisolone daily. On periodic follow-up, the patient was quite well without episodes of angioedema and no new skin lesions were seen. Our patient met all criteria for reactive macrophage activation syndrome (rMAS) outlined by Imashuku.<xref ref-type="bibr" rid="CIT1">1</xref></p>
    <table-wrap id="T0001" position="float">
      <label>Table 1</label>
      <caption>
        <p>Laboratory test results.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Laboratory data (normal values in parenthesis)</th>
            <th align="center" rowspan="1" colspan="1">Admission</th>
            <th align="center" rowspan="1" colspan="1">Before IVIG<xref ref-type="table-fn" rid="T000F1">a</xref></th>
            <th align="center" rowspan="1" colspan="1">After first IVIG<xref ref-type="table-fn" rid="T000F1">a</xref></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1">Erythrocyte sedimentation rate (2-13 mm/h)</td>
            <td align="center" rowspan="1" colspan="1">57</td>
            <td align="center" rowspan="1" colspan="1">16</td>
            <td align="center" rowspan="1" colspan="1">122</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">White blood cell count (4-10&#xD7;10<sup>9</sup>/L)</td>
            <td align="center" rowspan="1" colspan="1">11.8</td>
            <td align="center" rowspan="1" colspan="1">5.8</td>
            <td align="center" rowspan="1" colspan="1">11.0</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Hemoglobin (120-160 g/L)</td>
            <td align="center" rowspan="1" colspan="1">132</td>
            <td align="center" rowspan="1" colspan="1">78</td>
            <td align="center" rowspan="1" colspan="1">101</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Platelet count (140-440&#xD7;10<sup>9</sup>/L)</td>
            <td align="center" rowspan="1" colspan="1">203</td>
            <td align="center" rowspan="1" colspan="1">33</td>
            <td align="center" rowspan="1" colspan="1">249</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">C reactive protein (0-5 mg/L)</td>
            <td align="center" rowspan="1" colspan="1">143</td>
            <td align="center" rowspan="1" colspan="1">88.2</td>
            <td align="center" rowspan="1" colspan="1">28.7</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Aspartate aminotransferase (7-49 IU/L)</td>
            <td align="center" rowspan="1" colspan="1">28</td>
            <td align="center" rowspan="1" colspan="1">720</td>
            <td align="center" rowspan="1" colspan="1">54</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Alanine aminotransferase (7-49 IU/L)</td>
            <td align="center" rowspan="1" colspan="1">35</td>
            <td align="center" rowspan="1" colspan="1">500</td>
            <td align="center" rowspan="1" colspan="1">75</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Lactate dehydrogenase (170-430 IU/L)</td>
            <td align="center" rowspan="1" colspan="1">361</td>
            <td align="center" rowspan="1" colspan="1">3206</td>
            <td align="center" rowspan="1" colspan="1">335</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Ferritin (10-300 mg/L)</td>
            <td align="center" rowspan="1" colspan="1">12200</td>
            <td align="center" rowspan="1" colspan="1">43700</td>
            <td align="center" rowspan="1" colspan="1">8300</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Fibrinogen (2-4.5 g/L)</td>
            <td align="center" rowspan="1" colspan="1">6.1</td>
            <td align="center" rowspan="1" colspan="1">1.4</td>
            <td align="center" rowspan="1" colspan="1">4.0</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">D-dimer (0.06-0.25 mg/ml)</td>
            <td align="center" rowspan="1" colspan="1">0.15</td>
            <td align="center" rowspan="1" colspan="1">4.36</td>
            <td align="center" rowspan="1" colspan="1">0.30</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="T000F1">
          <label>a</label>
          <p>IVIG = intravenous immunoglobulin</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <fig id="F0001" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Maculopapular rash.</p>
      </caption>
      <graphic xlink:href="ASM-30-88-g001"/>
    </fig>
    <fig id="F0002" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Bone marrow aspirate shows increased number of histiocytes with active hemophagocytosis (Hematoxylin stain &#xD7;200 magnification).</p>
      </caption>
      <graphic xlink:href="ASM-30-88-g002"/>
    </fig>
    <fig id="F0003" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Real-time PCR that confirmed parvovirus B19 (arrow shows negative control sample).</p>
      </caption>
      <graphic xlink:href="ASM-30-88-g003"/>
    </fig>
    <p>Acute parvovirus B19 infection can be diagnosed by demonstrating a four-fold rise in serum B19-specific IgG antibody titers, as in our case. B19 specific DNA or antigens can be detected for months or even years after infection.<xref ref-type="bibr" rid="CIT2">2</xref><xref ref-type="bibr" rid="CIT3">3</xref> We speculate that the presence of acute parvovirus B19 infection was a trigger for rMAS.<xref ref-type="bibr" rid="CIT4">4</xref> Lymphocytic vasculitis is a reactive process.<xref ref-type="bibr" rid="CIT5">5</xref><xref ref-type="bibr" rid="CIT6">6</xref> Purpura pigmentosa chronica, fixed drug eruption, urticarial vasculitis, allergic vasculitis, and the vasculitis of Sjogren syndrome are known to have lymphocytic vasculitis. We conclude that rMAS might represent a subgroup of patients with systemic inflammatory response amenable to IVIG treatment. Given early, IVIG may interrupt the processes that lead to macrophage overactivation.</p>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="CIT1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emmenegger</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Reimers</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Fux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bihl</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Semela</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation</article-title>
          <source>Swiss Med Wkly</source>
          <year>2002</year>
          <volume>132</volume>
          <fpage>230</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">12087489</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Musiani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zerbini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gentilomi</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Parvovirus B 19 clearance from peripheral blood after acute infection</article-title>
          <source>J Infect Dis</source>
          <year>1995</year>
          <volume>172</volume>
          <fpage>1360</fpage>
          <pub-id pub-id-type="pmid">7594678</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cassinotti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Burtonboy</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fopp</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Siegl</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Evidence for persistence of human parvovirus B 19 DNA in bone marrow</article-title>
          <source>J Med Virol</source>
          <year>1997</year>
          <volume>53</volume>
          <fpage>229</fpage>
          <pub-id pub-id-type="pmid">9365887</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grom</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Natural killer cell dysfunction</article-title>
          <source>Arthritis&amp;Rheumatism</source>
          <year>2004</year>
          <volume>50</volume>
          <fpage>689</fpage>
          <lpage>698</lpage>
          <pub-id pub-id-type="pmid">15022306</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlson</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>KR</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous vasculitis update: neutrophilic muscular vessel and eosinophilic, granulomatous, and lymphocytic vasculitis syndromes</article-title>
          <source>Am J Dermatopathol</source>
          <year>2007</year>
          <volume>29</volume>
          <fpage>32</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">17284960</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kossard</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Defining lymphocytic vasculitis</article-title>
          <source>Australasian J Dermatol</source>
          <year>2000</year>
          <volume>41</volume>
          <fpage>149</fpage>
          <lpage>55</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
